GEORGE P. CANELLOS, M.D., F.A.C.P.; VINCENT T. DeVITA, M.D., F.A.C.P.; G. LENNARD GOLD, M.D., F.A.C.P.; BRUCE A. CHABNER, M.D., F.A.C.P.; PHILIP S. SCHEIN, M.D., F.A.C.P.; ROBERT C. YOUNG, M.D., F.A.C.P.
Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2, intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle. Only 2 of 25 patients responded to hormonal therapy or endocrine ablation. Twenty-seven of the 40 patients (68%) had a complete response (8 patients) or partial response (19 patients). Lung, soft tissue, and nodal metastases were the most responsive sites. The median duration of antitumor response was 8 months, with a median survival of 18 months for the responding group. The nonresponders had a median survival of 4 months. The toxicity was primarily hematologic and was especially severe in patients with functional liver impairment due to metastatic disease.
CANELLOS GP, DeVITA VT, GOLD GL, CHABNER BA, SCHEIN PS, YOUNG RC. Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on Survival. Ann Intern Med. ;84:389–392. doi: 10.7326/0003-4819-84-4-389
Download citation file:
Published: Ann Intern Med. 1976;84(4):389-392.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use